Mucosal Healing Predicts Sustained Clinical Remission in Patients With Early-Stage Crohn's Disease

Gastroenterology

Volumn 138, Issue 2, 2010, Pages 463-468

  Baert, Filip ^a   Moortgat, Liesbeth ^a   Van Assche, Gert ^b   Caenepeel, Philip ^c   Vergauwe, Philippe ^d   De Vos, Martine ^e   Stokkers, Pieter ^f   Hommes, Daniel ^g   Rutgeerts, Paul ^b   Vermeire, Severine ^b   D'Haens, Geert ^h  

^a Heilig Hart Ziekenhuis   (Belgium)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c DEPARTMENT OF CARDIOLOGY   (Belgium)

^d Department of Laboratory Medicine   (Belgium)

^e GHENT UNIVERSITY HOSPITAL   (Belgium)

^f ACADEMIC MEDICAL CENTER   (Netherlands)

^g LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^h IMELDA HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; C REACTIVE PROTEIN; CORTICOSTEROID; INFLIXIMAB; METHOTREXATE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROHN DISEASE; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTESTINE MUCOSA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; REMISSION; REPEATED DRUG DOSE; TISSUE REPAIR;

EID: 75449114677     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2009.09.056     Document Type: Article

References (14)

1. D'Haens G., Baert F., Van Assche G., et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet 371 (2008) 660-667
2. Frøslie K.F., Jahnsen J., Moum B.A., Vatn M.H., and IBSEN Group. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology 133 (2007) 412-422
3. Daperno M., D'Haens G., Van Assche G., et al. Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD. Gastrointest Endosc 60 (2004) 505-512
4. Travis S.P., Stange E.F., Lémann M., et al. European evidence based consensus on the diagnosis and management of Crohn's disease: current management. Gut 55 suppl 1 (2006) i16-i35
5. Rutgeerts P., Geboes K., Vantrappen G., et al. Natural history of recurrent Crohn's disease at the ileocolonic anastomosis after curative surgery. Gut 25 (1984) 665-672
6. Rutgeerts P., Geboes K., Vantrappen G., et al. Predictability of the postoperative course of Crohn's disease. Gastroenterology 99 (1990) 956-963
7. D'Haens G., Geboes K., and Rutgeerts P. Endoscopic and histologic healing of Crohn's ileo colitis with azathioprine. Gastrointest Endosc 50 (1999) 667-671
8. Hanauer S.B., Feagan B.G., Lichtenstein G.R., et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 359 (2002) 1541-1549
9. D'Haens G.R., Noman M., Baert F., et al. Endoscopic healing after infliximab treatment for Crohn's disease provides a longer time to relapse. Gastroenterology 122 (2002) 776 (A)
10. Rutgeerts P., Diamond R.H., Bala M., et al. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease. Gastrointest Endosc 63 (2006) 433-442
11. Goekoop-Ruiterman Y.P., De Vries-Bouwstra J.K., Allaart C.F., et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt Study): a randomized, controlled trial. Arthritis Rheum 52 (2005) 3381-3390
12. Desilva S., Kaplan G., and Panaccione R. Sequential therapies for Crohn's disease: optimizing conventional and biologic strategies. Rev Gastroenterol Disord 8 (2008) 109-116
13. Colombel J.F., Rutgeerts P., Reinisch W., et al. Sonic: a randomized, double-blind, controlled trial. Comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. Gut 57 suppl II (2008) A1
14. Sipponen T., Savilahti E., Kärkkäinen P., et al. Fecal calprotectin, lactoferrin, and endoscopic disease activity in monitoring anti-TNF-alpha therapy for Crohn's disease. Inflamm Bowel Dis 14 (2008) 1392-1398